{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003966","form_type":"8-K","ticker":"STIM","cik":"0001227636","company_name":"Neuronetics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.607487+00:00","generated_at":"2026-06-07T02:01:31.771700+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Neuronetics reports preliminary Q4 revenue over $20M, record treatment session revenue","bullets":["Preliminary Q4 2023 total revenue >$20M (guidance $19-21M); U.S. NeuroStar system revenue ~$4.5M on 59 system shipments.","U.S. Treatment Session revenue >$14.5M (company record, +20% YoY); local consumable revenue +33% YoY.","Generated positive cash flow >$1M in Q4; ended 2023 with cash and equivalents ~$59M.","Full year 2023 preliminary revenue >$71M (guidance $70-72M); momentum cited across key customer segments.","Next phase of Better Me Guarantee Provider pilot to launch Jan 22, 2024 with ~100 sites; over 275 sites eligible later in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003966","json":"https://secwatch.observer/filing/0001193125-24-003966.json","markdown":"https://secwatch.observer/filing/0001193125-24-003966.md","text":"https://secwatch.observer/filing/0001193125-24-003966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1227636/000119312524003966/0001193125-24-003966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1227636/000119312524003966/d291263d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:01:31.771700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4893c3367279f20b649a01a7a2332aa8cc46566e","claim":"Neuronetics, Inc. reported the three months ended December 31, 2023 results: revenue over $20 million.","evidence_excerpt":"Preliminary unaudited total revenue is expected to be over $20 million as compared to previously stated guidance of $19.0 to $21.0 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1227636/000119312524003966/0001193125-24-003966-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2023"},{"label":"Revenue","value":"over $20 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"b3fbfdf9b7bbd613a69e45ab59bb3ff9cb8964ee","claim":"Neuronetics, Inc. reported the twelve months ended December 31, 2023 results: revenue over $71 million.","evidence_excerpt":"Preliminary unaudited total revenue is expected to be over $71 million as compared to previously stated guidance of $70.0 to $72.0 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1227636/000119312524003966/0001193125-24-003966-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the twelve months ended December 31, 2023"},{"label":"Revenue","value":"over $71 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}